Edition:
India

Exact Sciences Corp (EXAS.OQ)

EXAS.OQ on NASDAQ Stock Exchange Capital Market

86.24USD
6 Dec 2019
Change (% chg)

$2.63 (+3.15%)
Prev Close
$83.61
Open
$84.02
Day's High
$86.77
Day's Low
$84.02
Volume
595,061
Avg. Vol
610,646
52-wk High
$123.94
52-wk Low
$53.09

Latest Key Developments (Source: Significant Developments)

Genomic Health Stockholders Approve Proposed Acquisition By Exact Sciences
Friday, 8 Nov 2019 

Nov 7 (Reuters) - Genomic Health: :GENOMIC HEALTH STOCKHOLDERS APPROVE PROPOSED ACQUISITION BY EXACT SCIENCES.CO AND EXACT SCIENCES EXPECT TO CLOSE TRANSACTION ON FRIDAY, NOVEMBER 8.  Full Article

Exact Sciences Posts Q3 Loss Per Share Of $0.31
Wednesday, 30 Oct 2019 

Oct 29 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES REPORTS THIRD-QUARTER REVENUE GROWTH OF 85 PERCENT TO $219 MILLION.Q3 LOSS PER SHARE $0.31.SEES FY 2019 REVENUE $802 MILLION TO $810 MILLION.Q3 REVENUE $219 MILLION VERSUS REFINITIV IBES ESTIMATE OF $216.1 MILLION.Q3 EARNINGS PER SHARE ESTIMATE $-0.41 -- REFINITIV IBES DATA.COMPANY ANTICIPATES REVENUE OF $802-$810 MILLION DURING 2019.  Full Article

Exact Sciences Sees FY 2019 Revenue Of $800 Million To $810 Million
Monday, 29 Jul 2019 

July 29 (Reuters) - Exact Sciences Corp ::Q2 LOSS PER SHARE $0.30.SEES FY 2019 REVENUE $800 MILLION TO $810 MILLION.Q2 REVENUE $200 MILLION VERSUS REFINITIV IBES ESTIMATE OF $182.1 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.56 -- REFINITIV IBES DATA.UPDATED FY GUIDANCE DOES NOT INCLUDE IMPACT OF PENDING COMBINATION WITH GENOMIC HEALTH.FY2019 REVENUE VIEW $747.2 MILLION -- REFINITIV IBES DATA.  Full Article

Exact Sciences Q1 Loss Per Share $0.66
Wednesday, 1 May 2019 

April 30 (Reuters) - Exact Sciences Corp ::Q1 LOSS PER SHARE $0.66.Q1 REVENUE $162 MILLION VERSUS REFINITIV IBES ESTIMATE OF $153 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.65 -- REFINITIV IBES DATA.ANTICIPATES REVENUE OF $725-$740 MILLION DURING 2019, AN INCREASE FROM PRIOR GUIDANCE OF $710-730 MILLION.FY2019 REVENUE VIEW $729.4 MILLION -- REFINITIV IBES DATA.  Full Article

Jana Partners Dissolves Share Stake In Alphabet, Facebook; Cuts In Microsoft, GM
Wednesday, 14 Nov 2018 

Nov 14 (Reuters) - :JANA PARTNERS LLC DISSOLVES SHARE STAKE OF CLASS A CAPITAL STOCK IN ALPHABET INC - SEC FILING.JANA PARTNERS LLC DISSOLVES SHARE STAKE IN FACEBOOK INC.JANA PARTNERS LLC CUTS SOLE SHARE STAKE IN MICROSOFT CORP BY 55.0 PERCENT TO 334,359 SHARES.JANA PARTNERS LLC CUTS SOLE SHARE STAKE IN GENERAL MOTORS CO BY 56 PERCENT TO 280,560 SHARES.JANA PARTNERS LLC CUTS SOLE SHARE STAKE IN ALIBABA GROUP HOLDING LTD BY 20.8 PERCENT TO 348,055 SPONSORED ADS.JANA PARTNERS LLC TAKES SOLE SHARE STAKE OF 65,000 SHARES IN UNITED STATES STEEL CORP.JANA PARTNERS LLC TAKES SOLE SHARE STAKE OF 4.6 MILLION SHARES IN FALCON MINERALS CORP.JANA PARTNERS LLC TAKES SOLE SHARE STAKE OF 1.2 MILLION SHARES IN EXACT SCIENCES CORP.JANA PARTNERS LLC DISSOLVES SOLE SHARE STAKE IN AUTOMATIC DATA PROCESSING INC.JANA PARTNERS LLC CUTS SOLE SHARE STAKE IN AGILENT TECHNOLOGIES INC BY 33.6 PERCENT TO 810,314 SHARES.JANA PARTNERS LLC: CHANGE IN HOLDINGS ARE AS OF SEPTEMBER 30, 2018 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF JUNE 30, 2018.  Full Article

Cologuard Revenue Increased 63 Percent To $118 Million In Q3
Wednesday, 31 Oct 2018 

Oct 30 (Reuters) - Exact Sciences Corp ::COLOGUARD® REVENUE INCREASED 63 PERCENT TO $118 MILLION, AND COLOGUARD TEST VOLUME GREW 49 PERCENT TO 241,000 DURING THIRD QUARTER.Q3 LOSS PER SHARE $0.37.Q3 REVENUE $118.3 MILLION VERSUS I/B/E/S VIEW $109.3 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.42 -- THOMSON REUTERS I/B/E/S.ANTICIPATES REVENUE OF $435-$440 MILLION FOR 2018.FY2018 REVENUE VIEW $428.6 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Exact Sciences Strengthens Pipeline Capabilities With Acquisition Of Biomatrica
Thursday, 18 Oct 2018 

Oct 18 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES STRENGTHENS PIPELINE CAPABILITIES WITH ACQUISITION OF BIOMATRICA, A LEADING PROVIDER OF BIOLOGICAL SAMPLE PRESERVATION TECHNOLOGY.EXACT SCIENCES CORP - FINANCIAL TERMS OF TRANSACTION ARE NOT BEING DISCLOSED..EXACT SCIENCES CORP - BIOMATRICA WILL REMAIN BASED IN SAN DIEGO.EXACT SCIENCES - INTENDS TO USE BIOMATRICA'S PROPRIETARY TECHNOLOGY TO SUPPORT ONGOING & FUTURE DEVELOPMENT OF ITS OWN BLOOD-BASED CANCER DETECTION TESTS.  Full Article

Exact Sciences Says Enter Agreement Through 2021 With Pfizer To Co-Promote Cologuard
Wednesday, 22 Aug 2018 

Aug 22 (Reuters) - Exact Sciences Corp ::EXACT SCIENCES SAYS CO, PFIZER ENTER INTO AGREEMENT THROUGH 2021 TO CO-PROMOTE COLOGUARD, A STOOL DNA SCREENING TEST FOR COLORECTAL CANCER.EXACT SCIENCES SAYS AS PER AGREEMENT, PFIZER WILL CO-PROMOTE COLOGUARD WITH CO BEGINNING IN Q4 2018.EXACT SCIENCES SAYS AS PER AGREEMENT, CO WILL MAINTAIN RESPONSIBILITY FOR ALL ASPECTS OF MANUFACTURING & LABORATORY OPERATIONS OF COLOGUARD.EXACT SCIENCES SAYS AS PER AGREEMENT, PFIZER WILL SHARE GROSS PROFITS & MARKETING EXPENSES EQUALLY ABOVE AN AGREED UPON BASELINE.  Full Article

Exact Sciences reports Q1 Loss Per Share of $0.33
Friday, 27 Apr 2018 

April 26 (Reuters) - Exact Sciences Corp ::Q1 LOSS PER SHARE $0.33.Q1 REVENUE $90.3 MILLION VERSUS I/B/E/S VIEW $86.9 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.37 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 REVENUE $420 MILLION TO $430 MILLION.FOR Q2, COMPANY ANTICIPATES COMPLETING 220,000-230,000 COLOGUARD TESTS.  Full Article

Exact Sciences Q4 Loss Per Share $0.18
Friday, 23 Feb 2018 

Feb 22 (Reuters) - Exact Sciences Corp ::COLOGUARD® REVENUE INCREASED 168 PERCENT TO $266 MILLION.Q4 LOSS PER SHARE $0.18.Q4 REVENUE ROSE 148 PERCENT TO $87.4 MILLION.SEES FY 2018 REVENUE $420 MILLION TO $430 MILLION.ANTICIPATES COMPLETED COLOGUARD TEST VOLUME OF 900,000-920,000 TESTS DURING 2018..Q4 EARNINGS PER SHARE VIEW $-0.24, REVENUE VIEW $85.7 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Alexion Pharma rejects Elliott's push for 'proactive sale'

Alexion Pharmaceuticals Inc said on Friday its board of directors had unanimously rejected hedge fund Elliott Management's push for a "proactive sale" process of the entire company because it would not be in the best interest of shareholders.